1332301-87-7 Usage
Uses
Used in Pharmaceutical Industry:
Tert-butyl 4-(4-bromothiazol-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate is used as a precursor in the synthesis of pharmaceutical compounds for its potential antimicrobial and anticancer properties due to the presence of the bromothiazol group. tert-butyl 4-(4-bromothiazol-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate's complex structure allows for further chemical modifications to enhance its therapeutic effects and target specific biological pathways.
Used in Cardiovascular Drug Development:
In the cardiovascular field, tert-butyl 4-(4-bromothiazol-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate is utilized as a key intermediate in the development of new drugs aimed at treating various cardiovascular diseases. The dihydropyridine group within the compound is known to have vasodilatory effects, making it a valuable component in the creation of medications that can help manage conditions such as hypertension and angina.
Used in Antimicrobial Agents:
tert-butyl 4-(4-bromothiazol-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate is also considered for use as an antimicrobial agent, leveraging the bromothiazol group's known antimicrobial properties. This application is particularly relevant in the development of new antibiotics to combat drug-resistant bacteria, where the compound's unique structure may offer novel mechanisms of action.
Used in Research and Development:
Tert-butyl 4-(4-bromothiazol-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate serves as a valuable compound in academic and industrial research settings. Its complex structure and potential biological activities make it an interesting subject for studies aimed at understanding its mechanisms of action, optimizing its pharmaceutical properties, and exploring its use in various therapeutic areas.
Check Digit Verification of cas no
The CAS Registry Mumber 1332301-87-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,2,3,0 and 1 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1332301-87:
(9*1)+(8*3)+(7*3)+(6*2)+(5*3)+(4*0)+(3*1)+(2*8)+(1*7)=107
107 % 10 = 7
So 1332301-87-7 is a valid CAS Registry Number.
1332301-87-7Relevant academic research and scientific papers
GLP-1R AGONISTS AND USES THEREOF
-
Page/Page column 59; 73, (2020/10/21)
Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.
TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE
-
Page/Page column 39-40; 42, (2020/05/15)
The invention provides a variety of compounds having the structure of Formula I and uses of such compounds for treatment of various indications, including cancer as well as methods of treatment involving such compounds are also provided. The uses of the compounds may specifically include: bladder cancer, cholangiocarcinoma; colorectal cancer; diffuse large B-cell lymphoma (DLBC); liver cancer; ovarian cancer; thymoma; thyroid cancer; clear cell renal cell carcinoma (CCRCC); chromophobe renal cell carcinoma (ChRCC); prostate cancer; breast cancer; uterine cancer; pancreatic cancer; cervical cancer; uveal melanoma; acute myeloid leukemia (AML); head and neck cancer; small cell lung cancer (SCLC); lung adenocarcinoma sarcoma; mesothelioma; adenoid cystic carcinoma (ACC), sarcoma; testicular germ cell cancer; uterine cancer; pheochromocytoma and paraganglioma (PCPG); melanoma; glioma; glioblastoma multiforme; T-cell Acute Lymphoblastic Leukemia; T-cell Lympohoma, medulloblastoma; and neuroblastoma.
ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN
-
Page/Page column 86-87, (2011/09/19)
The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
